Peptides have become one of the fastest-growing topics in healthcare, wellness, and longevity medicine. While peptide-based medications have long been used in conventional medicine for conditions such as diabetes, osteoporosis, fertility, and hormone disorders, growing public awareness has expanded interest far beyond traditional applications.
For pharmacies, peptides represent more than a clinical trend, they are an emerging category with significant opportunities.
Traditional and emerging uses of peptides
FDA-approved peptide therapies
Many peptide therapies are already firmly established in modern medicine.
The most visible category of FDA-approved peptide medications today is GLP-1 and incretin-based therapy for diabetes, obesity, and metabolic health. Medications such as Ozempic, Wegovy, Mounjaro, and Zepbound have transformed conversations around chronic weight management and cardiometabolic care.
Other FDA-approved peptide medications include:
- Saxenda and Victoza
- Trulicity
- Byetta and Bydureon BCise
- Lupron Depot for hormone-related conditions
- Forteo for osteoporosis
- Additional FDA-approved peptide therapies used in endocrine, reproductive, and metabolic medicine, including calcitonin and gonadotropin-related products.
The peptide therapy pipeline continues to grow rapidly, with emerging medications such as Retatrutide, Amycretin, and CagriSema generating significant interest in obesity, diabetes, and cardiometabolic care.
As new peptide therapies move closer to potential FDA approval, pharmacies can expect continued growth in patient questions, prescription volume, and demand for counseling and support services related to these medications.
Emerging and high-interest peptide compounds:
Beyond FDA-approved medications, consumer interest has expanded into wellness, longevity, recovery, and performance-focused peptides. Several peptide and peptide-related compounds generating interest across wellness, longevity, and performance discussions include:
- BPC-157 – Commonly marketed toward recovery and injury support, tissue repair, and healing.
- TB-500 / Thymosin Beta-4 – Often associated with recovery, performance enhancement, mobility, and muscle repair.
- CJC-1295 – Commonly marketed for weight management, muscle growth and body composition, anti-aging, and growth hormone support.
- Ipamorelin – Often positioned around body composition, metabolic health, recovery, healthy aging, and hormone optimization.
- Sermorelin – Commonly associated with anti-aging, vitality, sleep, and growth hormone support.
- PT-141 / Bremelanotide – Primarily marketed toward sexual health and wellness.
- MK-677 (Ibutamoren) – Often marketed for muscle growth, recovery, metabolic health, performance, and growth hormone support.
Many are promoted through wellness clinics, fitness communities, anti-aging programs, and online peptide marketplaces, often with claims related to recovery, vitality, or performance despite limited clinical evidence and varying regulatory status.
For community pharmacists, peptide-related questions are becoming increasingly common, whether tied to FDA-approved medications, compounded products, or wellness trends.
Safety considerations and drug interactions
As peptide demand grows, pharmacists should be prepared to address both clinical and regulatory considerations.
Regulatory oversight is important as demand for compounded semaglutide, tirzepatide, and other peptide products continues to grow. Pharmacies considering peptide opportunities should closely monitor:
- FDA communications and enforcement priorities
- State board pharmacy requirements
- Bulk drug substance eligibility
- Supplier sourcing and API quality
- Labeling, traceability, and documentation standards
Not all peptide products are created equal. Online marketplaces and gray-market vendors may offer products with questionable purity, sourcing, or dosing accuracy. Vetting suppliers, obtaining certificates of analysis (COAs), and prioritizing pharmaceutical-grade ingredients are essential operational and patient safety considerations.
Additionally, safety considerations can vary significantly depending on the peptide therapy and patient population. Potential clinical concerns may include:
- Gastrointestinal effects such as nausea and vomiting
- Injection-site reactions
- Hormonal disruption or endocrine effects
- Edema or fluid retention
- Drug interactions and medication overlap
- Unrealistic patient expectations driven by marketing claims
Comprehensive medication reviews and medical history assessments remain essential when dispensing these medications.
The business side of peptides
Peptides are no longer a niche topic, as growing use in obesity treatment, metabolic health, wellness, and anti-aging care continues to increase patient interest and pharmacy conversations.
Several factors continue to drive market demand of peptides:
- Rising obesity treatment utilization
- Increased public awareness of GLP-1 medications
- Growth in telehealth and direct-to-consumer healthcare
- Consumer interest in preventative, personalized, and holistic care
- Expanding wellness and longevity markets
For community pharmacies, this trend creates opportunities that extend beyond dispensing.
Potential areas of growth may include:
- Weight management support services
- GLP-1 medication counseling
- Metabolic health education
- Wellness and integrative care conversations
- Peptide compounding pharmacy services (when operationally and regulatorily appropriate)
What community pharmacists should do
Pharmacies do not need to wait for the next wave of peptide expansion to begin building relevance in this space.
One of the strongest opportunities today is positioning the pharmacy as a holistic care destination. Community pharmacists can strengthen relationships by starting these overall well-being conversations now, even when peptide therapy is not the immediate focus.
Talk to patients about:
- Available treatment options today
- FDA-approved therapies versus investigational or off-label compounds
- Medication risks, benefits, and realistic expectations
- Lifestyle, nutrition, and supportive care considerations
- Product quality, sourcing, and online purchasing concerns
- Supplements & holistic products that can support their health goals
Education matters. Many patients encounter peptide information through social media, influencer marketing, or fragmented online sources. Pharmacies can differentiate themselves by providing balanced, evidence-informed guidance rooted in clinical care.
The pharmacies that build credibility now may be better prepared to meet future patient demand, evolving therapeutic trends, and changing healthcare expectations.
Looking ahead
The peptide landscape is expanding rapidly. While not every peptide compound is FDA-approved or supported by robust evidence, patient interest is undeniable and growing.
For community pharmacists, the opportunity is not simply to follow the trend. It is to understand the science, monitor the regulatory environment, educate patients responsibly, and position the pharmacy as a trusted partner in a changing therapeutic landscape.
ABOUT THE AUTHOR
Michelle Barney, PharmD
Clinical Solutions Manager, Lumistry
Michelle Barney is a Clinical Solutions Manager at Lumistry, where she brings the practicing pharmacist’s perspective into the creation and evolution of pharmacy technology solutions. A clinical pharmacist by training, Michelle has built her career across retail pharmacy and health technology, including serving as Vice President of Clinical Operations at VUCA Health prior to its acquisition by Lumistry. She has held leadership roles spanning clinical operations, product, and marketing, and brings firsthand experience managing pharmacy teams and workflows. In her current role, Michelle partners closely with cross-functional teams to ensure Lumistry’s products are rooted in real-world pharmacy needs—helping pharmacies work more efficiently, confidently, and effectively in their day-to-day practice.
